PLA1A and neoplasm: Checkpoint control of immune response is a likely compensatory mechanism used by tumor cells to manage remaining NMD-escape events, a notion in keeping with the elevated CPI clinical benefit rates we see in patients with even a small number of NMD-escape alterations.